Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by David Martinez and Ralph Baric.
David Martinez
Connection Strength
3.361
Ralph Baric
  1. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021 08 27; 373(6558):991-998.
    View in: PubMed
    Score: 0.952
  2. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
    View in: PubMed
    Score: 0.239
  3. Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2021 Feb; 590(7844):E22.
    View in: PubMed
    Score: 0.232
  4. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020 10; 586(7830):560-566.
    View in: PubMed
    Score: 0.225
  5. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020 07 23; 182(2):429-446.e14.
    View in: PubMed
    Score: 0.221
  6. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. mSphere. 2021 08 25; 6(4):e0027521.
    View in: PubMed
    Score: 0.060
  7. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 09 17; 373(6561):1372-1377.
    View in: PubMed
    Score: 0.060
  8. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
    View in: PubMed
    Score: 0.060
  9. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature. 2021 08; 596(7872):423-427.
    View in: PubMed
    Score: 0.060
  10. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 08 05; 184(16):4203-4219.e32.
    View in: PubMed
    Score: 0.059
  11. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 08; 596(7871):268-272.
    View in: PubMed
    Score: 0.059
  12. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
    View in: PubMed
    Score: 0.059
  13. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021 06; 594(7864):553-559.
    View in: PubMed
    Score: 0.059
  14. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021 05 12; 13(593).
    View in: PubMed
    Score: 0.059
  15. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. J Virol. 2021 Mar 16.
    View in: PubMed
    Score: 0.058
  16. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.058
  17. Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb; 590(7844):E25.
    View in: PubMed
    Score: 0.058
  18. Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. J Virol. 2021 Jan 20.
    View in: PubMed
    Score: 0.058
  19. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2020 11 24; 117(47):29832-29838.
    View in: PubMed
    Score: 0.057
  20. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 12 17; 383(25):2427-2438.
    View in: PubMed
    Score: 0.057
  21. High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell. 2020 10 15; 183(2):429-441.e16.
    View in: PubMed
    Score: 0.056
  22. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
    View in: PubMed
    Score: 0.056
  23. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020 10; 586(7830):583-588.
    View in: PubMed
    Score: 0.056
  24. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
    View in: PubMed
    Score: 0.056
  25. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
    View in: PubMed
    Score: 0.056
  26. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020 09; 26(9):1422-1427.
    View in: PubMed
    Score: 0.056
  27. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
    View in: PubMed
    Score: 0.056
  28. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020 06 11; 5(48).
    View in: PubMed
    Score: 0.055
  29. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 08 14; 369(6505):806-811.
    View in: PubMed
    Score: 0.055
  30. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 08 14; 369(6505):812-817.
    View in: PubMed
    Score: 0.055
  31. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. MAbs. 2020 01 01; 12(1):1778435.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.